Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,333 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control label Clear all
Active, not recruiting Phase 3 Interventional

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
51
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

NCT05262023
View directory record Official record
Conditions
Frontotemporal Dementia
Interventions
DNL593, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

NCT02873650
View directory record Official record
Conditions
Hepatic Impairment
Interventions
dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • DeBary, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 21, 2026, 1:18 AM EDT
Terminated Phase 2 Interventional Results available

A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

NCT04544410
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Tildacerfont/Placebo
Drug
Lead sponsor
Spruce Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 21, 2026, 1:18 AM EDT
Terminated Phase 3 Interventional

Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma

NCT00907413
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
ERCP and Photodynamic Therapy, ERCP only
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlotteville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 21, 2026, 1:18 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

NCT01732913
View directory record Official record
Conditions
Indolent Non-Hodgkin's Lymphomas
Interventions
Placebo, Rituximab, Idelalisib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
32
States / cities
Huntsville, Alabama • Chandler, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00871182
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Inhaled PT001, Inhaled Placebo, Tiotropium Handihaler
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Peoria, Arizona • Denver, Colorado • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cigarette Pack Inserts for Smoking Cessation

NCT04075682
View directory record Official record
Conditions
Smoking Cessation
Interventions
Inserts with efficacy messages, Pictorial warnings on packs
Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Ithaca, New York • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 2 Interventional Results available

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

NCT00658359
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Cyclosporine, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
37
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 21, 2026, 1:18 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

NCT07426380
View directory record Official record
Conditions
Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic, Renal Impairment, Renal Insufficiency, End Stage Kidney Disease
Interventions
LY3841136
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Not yet recruiting Phase 2 Interventional

HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients With Persistent Hypogonadism After ADT for Treatment of Localized Prostate Cancer

NCT07882862
View directory record Official record
Conditions
Prostate Cancer
Interventions
Clomiphene Citrate 25mg
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2037
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Denosumab on Cellular Biomarkers in the Human Breast

NCT02099461
View directory record Official record
Conditions
Healthy Volunteer, Female, Breast
Interventions
Denosumab, Percutaneous core needle breast biopsy
Drug · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
Cypress, California • Hollywood, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 21, 2026, 1:18 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

NCT03684642
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Efpeglenatide, Dulaglutide, Background therapy Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 21, 2026, 1:18 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Testing Ultra-processed Warning Labels and Not-Ultra-processed Labels in United States

NCT07863570
View directory record Official record
Conditions
Ultra-Processed Labels
Interventions
NIB: Label exposure in mock-up UPF and Not-UPF products, NIB+UPFWL: Label exposure in mock-up UPF and Not-UPF products, NIB+Not-UPF Black: Label exposure in mock-up UPF and Not-UPF products, NIB+Not-UPF Green: Label exposure in mock-up UPF and Not-UPF products
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
12,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Terminated Not applicable Interventional Results available

rTMS for Depressed Teens: A Sham-Controlled Trial, Part 2

NCT01804296
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Paul E. Croarkin
Other
Eligibility
12 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

NCT05921903
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA Investigational Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Chicago, Illinois • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

NCT04649151
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo, mRNA-1273.222
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
4,328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
48
States / cities
Banning, California • La Mesa, California • Lake Worth, Florida + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

NCT02104245
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 2 Interventional Results available

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

NCT04266795
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Pevonedistat, Venetoclax, Azacitidine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
23
States / cities
Gilbert, Arizona • La Jolla, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Active, not recruiting Phase 2 Interventional

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

NCT06924970
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Tebapivat, Tebapivat Matched Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
16 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Farmington, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

NCT05006573
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Benralizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Newport Beach, California • Northridge, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 21, 2026, 1:18 AM EDT
Not yet recruiting Phase 3 Interventional

Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

NCT06973629
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis
Interventions
Debamestrocel - MSC-NTF (NurOwn), Placebo
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
15
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Nutrition Labeling on Fast Food Choices

NCT00127660
View directory record Official record
Conditions
Healthy
Interventions
Menu: calories=yes, value pricing=no, Menu: calories=yes, value pricing = yes, Menu: calories=no, value pricing = no
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years and older
Enrollment
605 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 21, 2026, 1:18 AM EDT